Diseases
BioMarin now provides three FDA-approved therapies to patients with PKU, MPS I and MPS VI, and the company continues to work at a rapid pace to develop additional drugs for other patients suffering from a variety of rare genetic illnesses.
Following is a list of rare genetic diseases now being addressed at BioMarin.
To learn more about each product development program, click on selected links. You may also visit the Resource Library, or contact BioMarin Patient and Physician Support (BPPS) should you like to receive additional information.